SAB Biotherapeutics, Inc. (SABS)
CIK 1833214 · all EDGAR filings →
Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.
Shares outstanding over time
Latest: 90.1M shares as of Nov 2, 2026 (10-Q).⊙
Cash runway
Self-funding
profitable · generates cash
Full breakdown: cash runway tool · source filing →
Warrants
| Tranche | Warrants | Exercise price | Term | Notes |
|---|---|---|---|---|
| Pre-Funded Warrants | 2.8M | $0.0001 | — | — |
| Preferred PIPE Series B Warrants | 1.4M | not tagged | — | — |
| Enrollment Date Warrants | 1.0M | $218.75 | — | — |
| Preferred Pipe Placement Agent Warrants | 850,119 | $6.3 | — | — |
| Pipe Private Placement Warrants | 736,337 | $10.8 | — | — |
| Pipe Warrants | 736,337 | not tagged | — | — |
| Public Warrants | 575,000 | not tagged | — | FV $81,000 |
| Business Combination Public Warrants | 575,000 | not tagged | — | — |
| Release Date Warrants | 500,000 | $175 | — | — |
| Preferred Tranche C Warrants | 107,115 | not tagged | 5y | — |
| Preferred Tranche B Warrants | 42,846 | not tagged | 0.2y | — |
| Ladenburg Agreement Warrants | 30,000 | $5.424 | 3y | — |
Tranches exactly as the company dimensioned them in its 10-Q filed Nov 5, 2026 →. Groupings can overlap (a “Series E and F” row is not additive with a “Series E” row), so do not sum this column. A tranche the filer did not tag is absent here, not absent from the cap table. DOWN-ROUND = the filer tagged price-protection accounting scoped to that tranche.
Warrants outstanding: 2.8M underlying shares, as reported Mar 31, 2026 (10-Q).
Reported exercise price: $0.01 (aggregate figure as tagged; individual tranches vary).
Rough fully diluted estimate: 92.8M = 90.1M O/S + 2.8M warrant shares. An estimate, not a filing figure: it ignores converts, options and RSUs, and the two inputs carry different as-of dates.
Convertible notes
No convertible-note facts tagged in the 10-Q filed Nov 5, 2026. If convertible notes exist, their terms live in exhibit prose for this filer and are not parsed; absence of a tag is not proof of absence. The exhibits are the ground truth.
Fully diluted build-up
Shares outstanding plus every potential-share instrument the filer tagged in XBRL, each at its own as-of date. An estimate assembled from filed figures, not a filing figure itself.
| Shares outstanding | 90.1M | Nov 2, 2026 |
| + Pre-Funded Warrants (if exercised) | 2.8M | Sep 30, 2026 |
| + Preferred PIPE Series B Warrants (if exercised) | 1.4M | Sep 30, 2026 |
| + Enrollment Date Warrants (if exercised) | 1.0M | Jul 21, 2025 |
| + Preferred Pipe Placement Agent Warrants (if exercised) | 850,119 | Sep 30, 2026 |
| + Pipe Private Placement Warrants (if exercised) | 736,337 | Sep 30, 2026 |
| + Pipe Warrants (if exercised) | 736,337 | Sep 30, 2026 |
| + Public Warrants (if exercised) | 575,000 | Oct 22, 2026 |
| + Business Combination Public Warrants (if exercised) | 575,000 | Sep 30, 2026 |
| + Release Date Warrants (if exercised) | 500,000 | Jul 21, 2025 |
| + Preferred Tranche C Warrants (if exercised) | 107,115 | Sep 30, 2026 |
| + Preferred Tranche B Warrants (if exercised) | 42,846 | Dec 31, 2024 |
| + Ladenburg Agreement Warrants (if exercised) | 30,000 | Mar 21, 2023 |
| Fully diluted estimate | 99.4M | +10.3% vs O/S |
Still excluded, because the filer does not tag them in countable form: employee options and RSUs, any instrument living only in exhibit prose, and instruments above missing a share count. Inputs carry different as-of dates, shown per row. Each figure traces to the tranche and note tables above and their cited filings.
Registrations and offerings
Registered offering capacity on live registrations: $1156.3Mfrom the structured fee exhibits; registered is not remaining, takedowns are not subtracted
Last 12 months: 2 executed · 1 registered.
Full history and shelf status: offering checker · S-3 shelf checker
Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.
Keep going: float checker · offering calendar · short-squeeze screener · full SABS workspace
Free to use. No account, no card.